论文部分内容阅读
目的:探讨硝苯地平控释片联合缬沙坦治疗老年2型糖尿病肾病合并高血压的临床效果。方法:选取来我院进行治疗的2型糖尿病肾病合并高血压老年患者62例,根据治疗方式分为3组,A组20例患者给与口服硝苯地平控释片进行治疗,B组20例患者给与口服缬沙坦胶囊进行治疗,C组22例患者给与硝苯地平控释片联合缬沙坦进行治疗。连续治疗6个月的时间。结果:治疗6个月之后,三组患者的舒张压(SBP)、收缩压(DBP)和24小时尿微量清蛋白排泄率(UAER)较治疗前均显著降低,组内比较差异具有统计学意义(P<0.05);而尿素氮(BUN)、血肌酐(SCr)和血钾(K+)与治疗前相比,差异无统计学意义(P>0.05)。治疗后,C组患者的舒张压(SBP)、收缩压(DBP)和24小时尿微量清蛋白排泄率(UAER)显著低于A组和B组患者,组间比较差异具有统计学意义(P<0.05)。结论:硝苯地平控释片联合缬沙坦治疗2型糖尿病肾病合并高血压具有疗效显著,无毒副作用,延缓肾病发展的临床效果。
Objective: To investigate the clinical effect of nifedipine controlled release tablets combined with valsartan in the treatment of elderly type 2 diabetic nephropathy complicated with hypertension. Methods: Totally 62 elderly patients with type 2 diabetic nephropathy with hypertension were enrolled in our hospital. They were divided into 3 groups according to the mode of treatment. A group of 20 patients were given oral nifedipine controlled release tablets for treatment. Group B, 20 patients Patients were given oral valsartan capsules for treatment, C group 22 patients were given nifedipine controlled release tablets combined with valsartan for treatment. Continuous treatment of 6 months time. Results: After 6 months of treatment, the SBP, DBP and UAER of the three groups were significantly lower than those before treatment, and the difference was statistically significant (P <0.05). There was no significant difference between BUN, SCr and K before treatment (P> 0.05). After treatment, the SBP, DBP and UAER in group C were significantly lower than those in group A and group B <0.05). Conclusion: Nifedipine controlled release tablets combined with valsartan in the treatment of type 2 diabetic nephropathy complicated with hypertension has significant curative effect, no toxic and side effects and delayed the clinical effect of nephropathy.